Loading...
Docoh

Gracell Biotechnologies (GRCL)

News

From Benzinga Pro
Gracell Biotechnologies: Q1 Earnings Insights
16 May 22
Earnings, News
Gracell Biotechnologies (NASDAQ:GRCL) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Gracell Biotechnologies Q1 EPS $(0.07) Beats $(0.21) Estimate
16 May 22
Earnings, News
Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.21) by 66.67 percent. This is a 72 percent increase over losses of $(0.25) per share
Earnings Scheduled For May 16, 2022
16 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Preview: Gracell Biotechnologies's Earnings
13 May 22
Earnings
Gracell Biotechnologies (NASDAQ:GRCL) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Gracell Biotechnologies will report an earnings per share (EPS) of $-0.21.
Gracell Biotech Offers Details Of Its Oral Abstract Presentation At American Society Of Clinical Oncology Meeting: Will Present On Jun. 5 at 10:35 a.m. EDT
28 Apr 22
Biotech, News, FDA, Events, General
Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO,
Gracell Biotechnologies' Abstract On GC012F Accepted For Presentation At 2022 ASCO Annual Meeting
14 Apr 22
News, FDA, Events
Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
12 Apr 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
10 Apr 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
68 Biggest Movers From Yesterday
5 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation.
35 Stocks Moving In Monday's Mid-Day Session
4 Apr 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors.
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
4 Apr 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 Apr 22
Movers
BTIG Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $18
4 Apr 22
News, Price Target, Initiation, Analyst Ratings
BTIG analyst Justin Zelin initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $18.
12 Health Care Stocks Moving In Thursday's Intraday Session
24 Mar 22
Intraday Update, Markets, Movers
96 Biggest Movers From Yesterday
15 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share.
12 Health Care Stocks Moving In Monday's Intraday Session
14 Mar 22
Intraday Update, Markets, Movers
Stocks That Hit 52-Week Lows On Monday
14 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 671 companies achieved new lows for the year.
50 Stocks Moving In Monday's Mid-Day Session
14 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share.
Gracell Biotechnologies: Q4 Earnings Insights
14 Mar 22
Earnings, News
Gracell Biotechnologies (NASDAQ:GRCL) reported its Q4 earnings results on Monday, March 14, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Gracell Biotechnologies Q4 EPS $(0.30) Beats $(0.33) Estimate
14 Mar 22
Earnings, News
Gracell Biotechnologies (NASDAQ:GRCL) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 60 percent increase over losses of $(0.75) per share

Press releases

From Benzinga Pro
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
19 May 22
Press Releases
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
16 May 22
Earnings, Press Releases
Presented early clinical data from a first-in-human Phase 1 investigator-initiated trial (IIT) of allogeneic TruUCAR candidate GC502 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at AACR 2022;
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress
12 May 22
Press Releases
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company
Gracell Biotechnologies to Participate in Three Investor Conferences in May
4 May 22
News, Press Releases
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 04, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and
Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting
28 Apr 22
Press Releases
Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO,
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
22 Apr 22
Press Releases
SAN DIEGO, Calif. and SUZHOU, China, April 22, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
14 Apr 22
Press Releases
PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL
8 Apr 22
Press Releases
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
14 Mar 22
Earnings, Health Care, Press Releases
Plan to file U.S. IND for lead program FasTCAR-T GC012F for relapse and/or refractory multiple myeloma (RRMM) during second half of 2022Allogeneic TruUCAR-T GC502 currently being investigated in a first-in-human
Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference
10 Mar 22
News, Press Releases
PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing
Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
8 Mar 22
Press Releases
Gracell to present first-in-human data on GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform
22 Feb 22
Press Releases
SUZHOU, China, and PALO ALTO, Calif., Feb. 22, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated